<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharmacol Sin</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharmacol. Sin</journal-id><journal-title-group><journal-title>Acta Pharmacologica Sinica</journal-title></journal-title-group><issn pub-type="ppub">1671-4083</issn><issn pub-type="epub">1745-7254</issn><publisher><publisher-name>Springer Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7298161</article-id><article-id pub-id-type="publisher-id">438</article-id><article-id pub-id-type="doi">10.1038/s41401-020-0438-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Overview of therapeutic drug research for COVID-19 in China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Heng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fei-fei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xin-na</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Pei-lan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tong</surname><given-names>Xian-kun</given-names></name><address><email>xktong@simm.ac.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zuo</surname><given-names>Jian-ping</given-names></name><address><email>jpzuo@simm.ac.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000119573309</institution-id><institution-id institution-id-type="GRID">grid.9227.e</institution-id><institution>Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, </institution></institution-wrap>Shanghai, 201203 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1797 8419</institution-id><institution-id institution-id-type="GRID">grid.410726.6</institution-id><institution>University of Chinese Academy of Sciences, </institution></institution-wrap>Beijing, 100049 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution>Laboratory of Immunology and Virology, </institution><institution>Shanghai University of Traditional Chinese Medicine, </institution></institution-wrap>Shanghai, 201203 China </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>6</month><year>2020</year></pub-date><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>17</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; CPS and SIMM 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>novel coronavirus pneumonia</kwd><kwd>therapeutic drugs</kwd><kwd>anti-SARS-CoV-2 agents</kwd><kwd>favipiravir</kwd><kwd>hydroxychloroquine</kwd><kwd>traditional Chinese medicine</kwd></kwd-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">In December 2019, a new type of unexplained pneumonia&#x000a0;appeared in the South China Seafood Wholesale Market in Wuhan, Hubei Province, but its source has not yet been found. To confirm the cause, whole-genome sequencing of samples from patients with this unexplained pneumonia revealed a beta-coronavirus that had never been seen before, which was different from SARS-CoV and MERS-CoV [<xref ref-type="bibr" rid="CR1">1</xref>]. After the alert of this new pathogen, China quickly took measures to completely block off Hubei Province and implemented a quarantine policy nationwide to keep the outbreak under control. This efficient process was also recognized by the international WHO. This highly contagious new coronavirus was initially named 2019-nCoV. On Feb 11, 2020, the International Committee on Taxonomy of Viruses introduced the name &#x0201c;severe acute respiratory syndrome coronavirus 2&#x0201d; (SARS-CoV-2) to refer to the virus, and the WHO named the related pneumonia coronavirus pneumonia (COVID-19).</p><p id="Par3">This article will go through basic virology of SARS-CoV-2 and review mainly the drugs used in the battle against COVID-19 in China.</p></sec><sec id="Sec2"><title>Virology</title><p id="Par4">By genome sequencing, it was found that SARS-CoV-2 has 82% sequence similarity with SARS-CoV [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], and through phylogenetic tree analysis, it has 96% homology with bat coronaviruses at the genome level, for which reason bats were inferred to be the host for SARS-CoV-2 [<xref ref-type="bibr" rid="CR4">4</xref>].&#x000a0;The genome structure of SARS-CoV-2 is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>The genome of SARS-CoV-2 [<xref ref-type="bibr" rid="CR3">3</xref>].</p></caption><graphic xlink:href="41401_2020_438_Fig1_HTML" id="d30e263"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>The possible life cycle of SARS-CoV-2 [<xref ref-type="bibr" rid="CR10">10</xref>].</p></caption><graphic xlink:href="41401_2020_438_Fig2_HTML" id="d30e275"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Registered clinical trials for COVID-19 drugs [<xref ref-type="bibr" rid="CR11">11</xref>]. Clinical trials with ethics committee approval and signed informed consent were pooled from the ChiCTR database (<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn">www.chictr.org.cn</ext-link>) (as of 10 Mar), and drugs involved in these trials were identified and categorized manually.</p></caption><graphic xlink:href="41401_2020_438_Fig3_HTML" id="d30e293"/></fig></p><p id="Par5">SARS-CoV-2 is a single-stranded positive-sense RNA virus and is classified in the order Nidovirales, Coronaviridae, and Coronavirus [<xref ref-type="bibr" rid="CR5">5</xref>]. Coronaviruses are a large class of viruses that can infect mammals and birds and can cause many diseases, such as respiratory, intestinal, liver, and nervous system diseases [<xref ref-type="bibr" rid="CR6">6</xref>]. Coronaviruses are divided into four groups: alpha-, beta-, gamma- and delta-coronaviruses [<xref ref-type="bibr" rid="CR7">7</xref>], and all known human pathogenic coronaviruses are beta-coronaviruses.</p><p id="Par6">The single-stranded RNA genome of SARS-CoV-2 is 29891 nucleotides in size. The genes of SARS-CoV-2 from 5&#x02032; to 3&#x02032; are a 5&#x02032; untranslated region, including 5&#x02032; leader sequences; and open reading frame (ORF) 1a/b; structural proteins, including the envelope glycoprotein spike (S), envelope (E), membrane (M) and nucleoprotein (N); accessory proteins, such as ORF3, 6, 7a, 7b, 8, and 9b; and a 3&#x02032;&#x000a0;untranslated region [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">ORF1a/b occupy two-thirds of the viral genome, and they encode two polyproteins, pp1a and pp1ab [<xref ref-type="bibr" rid="CR8">8</xref>]. These two polyproteins can be hydrolyzed into 16 nonstructural proteins (nsps), including papain-like protease (PLpro), 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), helicase, and exonuclease [<xref ref-type="bibr" rid="CR6">6</xref>]. The enveloped glycoprotein spike (S) forms a layer of glycoproteins protruding from the envelope and is closely related to virus infection of cells [<xref ref-type="bibr" rid="CR9">9</xref>]. There are multiple sequence segments in the receptor-binding domain of the S protein, which have high homology with SARS-CoV sequences, and some studies have confirmed that SARS-CoV-2 can bind to the ACE2 receptor on the cell surface, similar to SARS-CoV [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Two additional transmembrane glycoproteins,&#x000a0;envelope (E) and membrane (M), are incorporated into the virion. Nucleoprotein encapsulates the viral (+) RNA genome in the form of a spiral in the envelope&#x000a0;to prevent degradation. Accessory proteins do not participate in viral replication, but they interfere with the host innate immune response or have other unknown functions [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">The SARS-CoV-2 possible life cycle begins when the spike glycoprotein on the envelope binds to the ACE2 receptor, and membrane fusion occurs either directly with the host cell membrane or with the endosome membrane. After membrane fusion, the viral RNA genome is released into the cytoplasm, and the uncoated RNA is translated into two polyproteins. The&#x000a0;polyproteins are cleaved by the&#x000a0;protease encoded by ORF1a into the 16 nsps, which can form an RNA replicase-transcriptase complex [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. This complex drives the production of negative-sense RNA, which is used as a template for the full-length (+) RNA genome. During transcription, subgenomic RNAs are produced by discontinuous transcription and then transcribed into subgenomic (+) mRNA, which is translated into different structural proteins. The newly formed structural protein and viral genomic RNA combine to form a nucleocapsid. The viral particles bud into the ER&#x02013;Golgi intermediate compartment (ERGIC), and then the primary virion is released from the infected cells [<xref ref-type="bibr" rid="CR10">10</xref>].&#x000a0;&#x000a0;A diagram of&#x000a0; SARS-CoV-2 life cycle is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.</p></sec><sec id="Sec3"><title>Overview of COVID-19 drug-related clinical trials in China</title><p id="Par9">Due to the sudden emergence of SARS-CoV-2, no specific antiviral agents are available. However, many drugs under development are believed to have potential anti-SARS-CoV-2 activity due to common biological processes in the virus life cycle. Currently, there are ~200 domestic clinical trials of COVID-19 drugs from the Chinese Clinical Trial Registry (ChiCTR) as of 10 March, and most are for chemical drugs, Chinese patent medicines, and combinations. All of these clinical trials were registered in 2020, after the outbreak of COVID-19 [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par10">Among those COVID-19 treatment-related clinical trials, a total of 155 registered COVID-19 treatment drug-related interventional studies were obtained from the ChiCTR database (<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn">www.chictr.org.cn</ext-link>) with ethics committee approval and informed consent signed by 10 March.&#x000a0;Statistic information of these registered trials are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The study phase of each trial was extracted, and nearly 25% of these clinical trials were registered as phase 4 studies, which were&#x000a0;stated as &#x0201c;postmarketing drugs&#x0201d; or &#x0201c;phase IV clinical trials&#x0201d; by the ChiCTR definition. In phase four studies, many domestically approved Chinese patent drugs and chemical agents are being used to treat COVID-19 patients.</p><p id="Par11">With so many clinical trials registered in such a short period of time, we can see that China has responded to the epidemic in a timely manner and hopes to find SARS-CoV-2-specific medicines to end the epidemic as soon as possible. This urgent need propelled China&#x02019;s drug research ability to its full power, and this motivation involved many academic institutions, hospitals, and companies. This approach has also led to concerns about this phenomenon. Excessive research and drug trials can create the problem of squeezing each other for limited medical resources or even wasting them. This phenomenon and its impact on our medical system, as well as possible improvement in our medical administration, need thorough review and discussion at an appropriate time in the future.</p><p id="Par12">In these 155 pooled clinical trials, a number of approved chemical and biomacromolecule drugs have been used in COVID-19 treatment clinical trials for drug repurposing, most of which are nucleotide analogs and protease inhibitors against other viral pathogens, including influenza virus, HIV and HCV. Comprehensive information about the chemical agents used in COVID-19 drug clinical trials is shown in the table below&#x000a0;(Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Approved drugs used in COVID-19 repurpose clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Category</th><th>Drug name</th><th>Approved indication</th><th>Mechanism</th></tr></thead><tbody><tr><td rowspan="4">Biomacro-molecule</td><td>Tocilizumab</td><td>Rheumatoid arthritis</td><td>IL-6R antibody</td></tr><tr><td>Type I interferon (include IFN-&#x003b1; &#x00026; IFN-&#x003b2;)</td><td>Hairy cell leukemia, melanoma, AIDS-related Kaposi&#x02019;s sarcoma</td><td>Immune modulation</td></tr><tr><td>Thymosin a1</td><td>T cell defect, autoimmunity disease</td><td>T cell stimulation</td></tr><tr><td>rhG-CSF</td><td>Leukopenia</td><td>CSF receptor</td></tr><tr><td rowspan="26">Chemical Agent</td><td>Lopinavir/ritonavir</td><td>HIV</td><td>HIV-1 protease inhibitor</td></tr><tr><td>Emtritabine</td><td>HIV</td><td>Reverse transcriptase inhibitor</td></tr><tr><td>Azvudine</td><td>HIV</td><td>Reverse transcriptase inhibitor</td></tr><tr><td>Ribavirin</td><td>HCV</td><td>RdRp<sup>a</sup> inhibitor</td></tr><tr><td>Danorevir</td><td>HCV</td><td>HCV protease inhibitor</td></tr><tr><td>Ganovo</td><td>HCV</td><td>HCV protease inhibitor</td></tr><tr><td>Tenofovir</td><td>HBV</td><td>Reverse transcriptase inhibitor</td></tr><tr><td>Triazavirin</td><td>Flu</td><td>RdRp inhibitor</td></tr><tr><td>Favipiravir</td><td>Flu</td><td>RdRp inhibitor</td></tr><tr><td>Baloxavir Marboxil</td><td>Flu</td><td>Influenza virus cap-dependent endonuclease inhibitor</td></tr><tr><td>Arbidol</td><td>Flu</td><td>Virion entry inhibitor</td></tr><tr><td>Poly (I:C) Injection</td><td>Viral infection</td><td>Immune modulation</td></tr><tr><td>Carrimycin</td><td>Bacteria infection</td><td>Peptide acyltransferase inhibitor</td></tr><tr><td>Dihydroartemisinine/Piperaquine</td><td>Malaria</td><td>Multiple targets</td></tr><tr><td>Chloroquine<sup>b</sup></td><td>Malaria</td><td>Heme biocrystallization inhibitor</td></tr><tr><td>Suramin</td><td>Trypanosomes infection</td><td>Multiple targets</td></tr><tr><td>Ruxolitinib</td><td>Myelofibrosis</td><td>JAK1/JAK2 signaling inhibition</td></tr><tr><td>Leflunomide</td><td>Rheumatoid arthritis</td><td>Pyrimidine synthesis inhibitor</td></tr><tr><td>Tranilast</td><td>Bronchial asthma, Allergic disorders</td><td>Hematopoietic prostaglandin D synthase inhibitor</td></tr><tr><td>Ebastine</td><td>Allergic rhinitis, Chronic idiopathic urticaria</td><td>Histamine H<sub>1</sub>-receptor antagonist</td></tr><tr><td>Alpha lipoic acid</td><td>Diabetic multiple peripheral neuropathy</td><td>Antioxidant</td></tr><tr><td>Pirfenidone</td><td>Idiopathic pulmonary fibrosis</td><td>Collagen synthesis inhibition, Cytokine down-regulation</td></tr><tr><td>Bismuth potassium citrate</td><td>Gastric ulcer</td><td>Gastric mucosa protectant</td></tr><tr><td>Enoxaparin Sodium Injection</td><td>Venous thromboembolic disease</td><td>Xa factor inbihitor</td></tr><tr><td>Glycyrrhizinate</td><td>Premenstrual syndrome, Viral infections</td><td>Multiple targets</td></tr><tr><td>Glucocorticoid</td><td>Inflammatory conditions</td><td>Glucocorticoid receptor</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>RdRp, RNA-dependent RNA polymerase.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Antiviral agents suggested in the national protocol for COVID-19 treatment</title><p id="Par13">Although the mortality rate of SARS-CoV-2 is not as high as that of SARS-CoV and MERS-CoV, SARS-CoV-2 is more contagious, and studies have shown that it can be transmitted during the incubation period [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par14">To date, there are no specific vaccines or antiviral drugs against COVID-19. For the treatment of patients, isolation and symptomatic supportive care are currently recommended, including oxygen therapy, water, and dielectric balance, nutritional interventions and fluid management to reduce symptoms and prevent end-organ dysfunction [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. For the treatment of severe pneumonia, extracorporeal membrane oxygenation therapy is a new type of adjuvant treatment technology [<xref ref-type="bibr" rid="CR15">15</xref>], and gas exchange through cardiopulmonary bypass technology can reduce ventilator-related damage and oxygen toxicity damage to promote early patient recovery. However, the needs for specific technical skill and high expense limit its usage.</p><p id="Par15">A number of nonspecific antiviral agents have been recommended in the latest 7th trial version of the &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;. Table <xref rid="Tab2" ref-type="table">2</xref> shown below lists important information about currently available anti-SARS-CoV-2 drugs&#x000a0;(Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Current suggested drugs in COVID-19 treatment<sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug</th><th colspan="2">Dosage (For adult)</th><th>Route of administration</th><th colspan="2">Course of treatment</th></tr></thead><tbody><tr><td>IFN-&#x003b1;</td><td>5,000,000 U</td><td>Twice daily</td><td>Aerosol inhalation</td><td/><td/></tr><tr><td>Lopinavir/ritonavir</td><td>400&#x02009;mg/100&#x02009;mg</td><td>Twice daily</td><td>Oral</td><td>&#x02264;10 days</td><td/></tr><tr><td>Ribavirin</td><td>500&#x02009;mg</td><td>2&#x02013;3 times daily</td><td>Intravenous injection</td><td>&#x02264;10 days</td><td>Combination with interferon or lopinavir /ritonavir recommended</td></tr><tr><td>Chloroquine phosphate</td><td>500&#x02009;mg</td><td>Twice daily</td><td>Oral</td><td>7 days</td><td>18&#x02013;65 years old, weight 50&#x02009;kg</td></tr><tr><td>Chloroquine phosphate</td><td>500&#x02009;mg</td><td>Day 1&#x02013;2 twice daily; Day 3&#x02013;7 once daily</td><td>Oral</td><td>7 days</td><td>18&#x02013;65 years old, weight &#x0003c;50&#x02009;kg</td></tr><tr><td>Arbidol</td><td>200&#x02009;mg</td><td>Three times daily</td><td>Oral</td><td>&#x02264;10 days</td><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>According to the 7th trial version of &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;.</p></table-wrap-foot></table-wrap></p><sec id="Sec5"><title>IFN-&#x003b1;</title><p id="Par16">Type I interferons, including IFN-&#x003b1; and IFN-&#x003b2;, have broad-spectrum antiviral effects [<xref ref-type="bibr" rid="CR16">16</xref>]. IFN-&#x003b1; can directly inhibit virus replication or can achieve antiviral effects by activating innate or adaptive immunity [<xref ref-type="bibr" rid="CR17">17</xref>]. Many studies have proven that IFN-&#x003b1; has an antiviral effect on SARS-CoV [<xref ref-type="bibr" rid="CR18">18</xref>], and other experts discovered that IFN-&#x003b1; can prevent MERS-CoV infection and effectively inhibit the virus in the early stages of infection [<xref ref-type="bibr" rid="CR19">19</xref>]. Because it is also a coronavirus and highly homologous to SARS-CoV, IFN-&#x003b1; is recommended for the treatment of SARS-CoV-2 infection. According to the latest new &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;, IFN-&#x003b1; at a dose of ~5 million U or equivalent dose each time for adults is added to 2&#x02009;mL of sterile water, and it is aerosolized and inhaled twice a day [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec6"><title>Lopinavir/ritonavir</title><p id="Par17">Lopinavir was first approved in the United States in 2000 for the treatment of HIV infection [<xref ref-type="bibr" rid="CR20">20</xref>]. It is a protease inhibitor and is usually used in combination with ritonavir to increase its half-life through the inhibition of cytochrome P450 [<xref ref-type="bibr" rid="CR21">21</xref>]. In vitro studies have shown that lopinavir/ritonavir can inhibit the replication of MERS-CoV and SARS-CoV and exert antiviral effects [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. At present, the drug has been used in the clinical treatment of COVID-19 at a dose of 400&#x02009;mg/100&#x02009;mg for adults twice daily, and the course of treatment does not exceed 10 days [<xref ref-type="bibr" rid="CR13">13</xref>]. However, this treatment has certain toxic and side effects on the treatment of COVID-19. Therefore, its safety and effectiveness require further research. Recently, some clinical studies have shown that lopinavir/ritonavir treatment has no significant effect [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec7"><title>Ribavirin</title><p id="Par18">Ribavirin is a purine nucleoside analog with a broad-spectrum antiviral effect [<xref ref-type="bibr" rid="CR28">28</xref>]. It is used mainly to treat respiratory syncytial virus infection [<xref ref-type="bibr" rid="CR29">29</xref>] and in combination with interferon for hepatitis C [<xref ref-type="bibr" rid="CR30">30</xref>]. Ribavirin was widely used in 2003 to treat SARS-CoV infection, but when used alone, it seemed to have no effect and caused significant hemolysis in many patients [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. When ribavirin was combined with IFN-&#x003b2;, it had good antiviral activity in in vitro studies [<xref ref-type="bibr" rid="CR35">35</xref>]. Some studies have shown that in patients with severe MERS-CoV infection, ribavirin combined with IFN-&#x003b1;-2a treatment can significantly improve patient 14-day survival [<xref ref-type="bibr" rid="CR36">36</xref>]. Preliminary in vitro test results demonstrate that ribavirin can inhibit SARS-CoV-2 in a human cell line. In the latest &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;, it is recommended to use ribavirin at a dose of 500&#x02009;mg each time for adults and in combination with interferon or lopinavir/ritonavir, with 2&#x02013;3 intravenous infusions daily. The course of treatment does not exceed 10 days [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec8"><title>Chloroquine phosphate</title><p id="Par19">Chloroquine phosphate is an antimalarial drug that has been on the market for many years, and it also has a potential broad-spectrum antiviral effect [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. It can increase the pH of lysosomes to prevent virus fusion with the cell membrane and then block virus entry and infection [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par20">Some studies have found that the spike glycoprotein on the virus envelope binds to the ACE2 receptor to mediate SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Chloroquine phosphate has been reported to interfere with the glycosylation of the ACE2 receptor, thereby inhibiting the binding of SARS-CoV to cells and achieving therapeutic goals [<xref ref-type="bibr" rid="CR41">41</xref>]. Therefore, chloroquine phosphate is used to treat COVID-19, and in vitro experiments show that chloroquine phosphate does inhibit SARS-CoV-2 and that its EC<sub>50</sub> is 1.13&#x02009;&#x003bc;M [<xref ref-type="bibr" rid="CR39">39</xref>]. Apart from the above antiviral mechanism, chloroquine phosphate can continue to exert antiviral effects after SARS-CoV-2 invades cells, and it also has immunomodulatory activity to strengthen the antiviral effect [<xref ref-type="bibr" rid="CR42">42</xref>]. Therefore, chloroquine phosphate has been included in the &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d; and is undergoing clinical trials. Chloroquine phosphate is used for the treatment of COVID-19 in adults aged 18&#x02013;65 years. Those who weigh more than 50&#x02009;kg will receive 500&#x02009;mg twice daily for 7 days, while those who weigh less than 50&#x02009;kg will receive 500&#x02009;mg twice daily on days 1 and 2 and 500&#x02009;mg once daily on days 3&#x02013;7 [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec9"><title>Arbidol</title><p id="Par21">Arbidol is a non-nucleoside broad-spectrum antiviral drug for upper respiratory tract infections caused by influenza A and B viruses, and it was first approved in Russia [<xref ref-type="bibr" rid="CR43">43</xref>]. It can inhibit the adhesion of viruses to host cells and prevent them from invading human cells [<xref ref-type="bibr" rid="CR44">44</xref>]. At the same time, it can promote the synthesis of interferon, which can prevent influenza virus invasion and treat influenza virus infection [<xref ref-type="bibr" rid="CR45">45</xref>]. Some studies have confirmed that arbidol has a good effect against SARS-CoV and MERS-CoV infections [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Chinese scientists found in in vitro cell experiments that compared with a drug-untreated control group, 10&#x02013;30&#x02009;&#x003bc;M arbidol can effectively inhibit SARS-CoV-2 up to 60 times and significantly inhibit the pathological effects of the virus on cells [<xref ref-type="bibr" rid="CR48">48</xref>]. As described in the latest &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;, arbidol is used at a dose of 200&#x02009;mg for adults three times daily, and the course of treatment does not exceed 10 days [<xref ref-type="bibr" rid="CR13">13</xref>]. It has been reported that some patients have improved symptoms after receiving arbidol [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec></sec><sec id="Sec10"><title>Anticipated antiviral agents</title><sec id="Sec11"><title>Favipiravir</title><p id="Par22">Favipiravir is a nucleoside analog [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] with an ability to inhibit RNA-dependent polymerase [<xref ref-type="bibr" rid="CR52">52</xref>] and was approved for marketing in Japan in 2014. It is used for antiviral treatment of influenza A and B [<xref ref-type="bibr" rid="CR52">52</xref>] and can effectively inhibit Ebola virus, yellow fever virus [<xref ref-type="bibr" rid="CR53">53</xref>], etc. In vitro experiments have shown that favipiravir is effective for COVID-19 and that its EC<sub>50</sub> is 61.88&#x02009;&#x003bc;M [<xref ref-type="bibr" rid="CR39">39</xref>]. To date, some clinical trials of favipiravir in the treatment of COVID-19 have been carried out in China. Recent clinical studies have found that compared with the antiviral drug arbidol, the clinical effect of favipiravir is more significant. Nucleic acid positive-to-negative time, mean antipyretic time and cough remission time were all better than those of the arbidol group [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec12"><title>Remdesivir(GS-5734)</title><p id="Par23">Remdesivir&#x000a0;was first used to treat Ebola virus, and it has completed phase 2 clinical trials [<xref ref-type="bibr" rid="CR54">54</xref>]. As a nucleoside analog, it can interact with RdRp [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], and the triphosphate form of remdesivir will compete with adenosine triphosphate, leading to delayed chain termination and inhibiting viral replication and transcription [<xref ref-type="bibr" rid="CR57">57</xref>]. A number of in vitro studies have shown that remdesivir has inhibitory effects on a variety of human and animal coronaviruses [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. An in vivo study of remdesivir against SARS-CoV showed that remdesivir can reduce virus levels in the lungs of mice infected with SARS-CoV and reduce lung function damage caused by the virus [<xref ref-type="bibr" rid="CR60">60</xref>]. Moreover, some studies have found that the antiviral effect of remdesivir against MERS-CoV is better than that of lopinavir/ritonavir combined with IFN-&#x003b2; [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par24">According to the above evidence, remdesivir has been used to treat SARS-CoV-2, and in vitro experiments showed that remdesivir has a good inhibitory effect on SARS-CoV-2, with an EC<sub>50</sub> of 0.77&#x02009;&#x003bc;M [<xref ref-type="bibr" rid="CR39">39</xref>]. Recently, the first COVID-19 patient in the United States was treated with remdesivir on the 7th day of hospitalization, and their clinical symptoms were&#x000a0;improved significantly [<xref ref-type="bibr" rid="CR61">61</xref>]. At present, a phase three clinical trial of remdesivir for COVID-19 has been officially launched in China, and a total of 761 patients are planned to be enrolled in the study, which will be randomized, double-blind and placebo-controlled [<xref ref-type="bibr" rid="CR62">62</xref>].</p></sec><sec id="Sec13"><title>Hydroxychloroquine</title><p id="Par25">As a derivative of chloroquine, hydroxychloroquine has similar efficacy and few adverse reactions. Based on its characteristics of immunomodulation, antithrombotic activity, and improved inflammation, hydroxychloroquine has been used in the clinical treatment of systemic lupus erythematosus [<xref ref-type="bibr" rid="CR63">63</xref>]. Hydroxychloroquine has been shown to have anti-SARS-CoV activity in vitro [<xref ref-type="bibr" rid="CR64">64</xref>], and it is clinically safer than chloroquine [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Some clinical studies have found that after treatment with hydroxychloroquine, the viral load significantly decreases or even disappears, and azithromycin can enhance the antiviral effect [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p></sec></sec><sec id="Sec14"><title>Traditional Chinese medicine (TCM)</title><p id="Par26">Traditional Chinese medicine has played an important role in the treatment of previous outbreaks of viral infectious diseases, so it has once again received attention during this epidemic of COVID-19 [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In response to the outbreak, Chinese medicine experts provided different Chinese medicine prescriptions and proprietary Chinese medicines for selection at different stages of the clinical treatment period of diagnosed patients according to the principle of TCM syndrome differentiation. For example, for patients with fatigue and fever during the medical observation period, Jinhua Qinggan granules, Lianhua Qingwen capsules (granules) and Shufeng Jiedu capsules (granules) can be used, while for patients with fatigue and gastrointestinal discomfort, the Chinese patent medicine Huoxiang Zhengqi capsules (pills, liquid, and oral solution) can be used [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par27">Lianhua Qingwen capsules contain many Chinese herbal ingredients with antiviral effects, such as licorice. Glycyrrhizic acid, an extract of licorice, has been shown to inhibit virus replication and has been used clinically to treat HCV infection [<xref ref-type="bibr" rid="CR71">71</xref>]. Glycyrrhizic acid has been reported to inhibit the replication of SARS-CoV in vitro [<xref ref-type="bibr" rid="CR72">72</xref>]. For the reasons above, Lianhua Qingwen capsules have been used in the clinic and have a certain effect on improving clinical symptoms because they can obviously alleviate the symptoms of cough, fever, and fatigue in patients with COVID-19, reduce the proportion of severe cases, and shorten fever time [<xref ref-type="bibr" rid="CR73">73</xref>&#x02013;<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par28">In addition, lung cleansing and detoxifying decoction is also recommended for the treatment of confirmed cases in the latest &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d; [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par29">In addition to traditional Chinese medicine prescriptions, some traditional Chinese medicine ingredients also have certain potential for the treatment of SARS-CoV-2. Baicalin is a flavonoid compound isolated from the root of <italic>Scutellaria baicalensis</italic> and has been confirmed to inhibit SARS-CoV in vitro [<xref ref-type="bibr" rid="CR76">76</xref>]. Ginsenoside improves human immunity and has a curative effect on viral infection [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par30">Therefore, traditional Chinese medicine can also be used as an option to treat COVID-19. Many clinical trials have been launched to further analyze the safety and effectiveness of traditional Chinese medicine, and the traditional Chinese medicines mentioned above have been recommended in the latest &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d; [<xref ref-type="bibr" rid="CR13">13</xref>]&#x000a0;(Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Currently suggested Chinese patent medicine in COVID-19 treatment<sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical symptom</th><th>Suggested Chinese patent medicine</th></tr></thead><tbody><tr><td>Medical observation period</td><td>Huoxiang Zhengqi capsules (pills, liquid, oral solution); Jinhua Qinggan granules; Lianhua Qingwen capsules (granules); Shufeng Jiedu capsules (granules)</td></tr><tr><td>Severe cases</td><td>Xiyanping injection; Xuebijing injection; Reduning injection; Tanreqing injection; Xingnaojing injection</td></tr><tr><td>Critical cases</td><td>Xuebijing injection; Reduning injection; Tanreqing injection; Xingnaojing injection; Shenfu injection; Shengmai injection; Shenmai injection</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>According to the 7th trial version of &#x0201c;Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia&#x0201d;.</p></table-wrap-foot></table-wrap></p><sec id="Sec15"><title>Chinese patent medicine</title><p id="Par31">Chinese patent medicine is herbal medicines in traditional Chinese medicine modernized into a ready-to-use form, such as tablets, oral solutions, or dry suspensions. Chinese patent medicine has played very important roles in the domestic battle against COVID-19 in China, and many clinical investigations have started to more precisely evaluate its effects on COVID-19 patient treatment. Chinese patent medicine, as well as many herbal medicines, has been very useful in improving symptoms such as coughing, weakness, and digestive system disorders, as well as alleviating anxiety. Reports announced that up to 90% of COVID-19 patients in China have been given Chinese patent medicine or TCM prescriptions. A list of Chinese patent medicine currently undergoing COVID-19 clinical trials is shown below&#x000a0;(Table <xref rid="Tab4" ref-type="table">4</xref>) to present an overall message about Chinese patent medicine in COVID-19 treatment research (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Chinese patent medicine used in COVID-19 clinical trials<sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Registration number</th><th>Chinese patent medicine</th></tr></thead><tbody><tr><td>ChiCTR2000029769</td><td>Babaodan capsules</td></tr><tr><td>ChiCTR2000030704</td><td>Bufonis Venenum injection</td></tr><tr><td>ChiCTR2000029822</td><td>Honeysuckle decoction</td></tr><tr><td>ChiCTR2000030545</td><td>Honeysuckle oral solution</td></tr><tr><td>ChiCTR2000029755</td><td>Jingye Baidu granules</td></tr><tr><td>ChiCTR2000030255</td><td>Jingyin granules</td></tr><tr><td>ChiCTR2000029781</td><td>Kangbingdu granules</td></tr><tr><td>ChiCTR2000029991</td><td>Keqing capsules</td></tr><tr><td>ChiCTR2000029991</td><td>Kesuting syrup</td></tr><tr><td>ChiCTR2000030469</td><td>Liushenwan</td></tr><tr><td>ChiCTR2000030022</td><td>Pediatric Huatanzhike granules</td></tr><tr><td>ChiCTR2000029589</td><td>Reduning injection</td></tr><tr><td>ChiCTR2000030043</td><td>Shenfu injection</td></tr><tr><td>ChiCTR2000029780</td><td>Shenqi Fuzheng injection</td></tr><tr><td>ChiCTR2000029605</td><td>Shuanghuanglian oral solution</td></tr><tr><td>ChiCTR2000029742</td><td>Sodium Aescinate injection</td></tr><tr><td>ChiCTR2000029813</td><td>Tanreqing capsules</td></tr><tr><td>ChiCTR2000029432</td><td>Tanreqing injection</td></tr><tr><td>ChiCTR2000030033</td><td>Xiangxue antiviral oral solution</td></tr><tr><td>ChiCTR2000029756</td><td>Xiyanping injection</td></tr><tr><td>ChiCTR2000029381</td><td>Xuebijing injection</td></tr><tr><td>ChiCTR2000029434</td><td>Lianhua Qingwen capsules (granules)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Chinese patent medicine used in 155 pooled COVID-19 clinical trials (either alone or in combination with other drugs) were listed.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>Potential anti-SARS-CoV-2 targets</title><sec id="Sec17"><title>Spike protein</title><p id="Par32">Some studies have confirmed that SARS-CoV-2 infects cells through endocytosis via the ACE2 receptor on AT2 alveolar epithelial cells in the lungs [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. At present, the protein structure of the S protein and ACE2 interaction has been solved, providing reliable guidance for vaccine and drug design [<xref ref-type="bibr" rid="CR80">80</xref>]. Aiming at the mutual use of the S protein and ACE2 protein necessary for SARS-CoV-2 to enter host cells, multiple domestic research teams have discovered a variety of potential ACE2-binding agents through molecular docking virtual screening methods and artificial intelligence drug screening methods.</p></sec><sec id="Sec18"><title>Papain-like protease (PLpro)</title><p id="Par33">PLpro is a multifunctional protein with protease and phosphatase activity that is involved in viral replication and IFN antagonism [<xref ref-type="bibr" rid="CR81">81</xref>]. PLpro of SARS-CoV-2 and SARS-CoV have only 83% sequence similarity [<xref ref-type="bibr" rid="CR82">82</xref>]. However, the high-level structure of the protein that forms the active site is not altered in the two PLpro proteins [<xref ref-type="bibr" rid="CR83">83</xref>]. There are already domestic teams working to find potential inhibitors of PLpro through virtual screening, which needs to be confirmed by experiments.</p></sec><sec id="Sec19"><title>3C-like protease (3CLpro)</title><p id="Par34">The 3CLpro of SARS-CoV-2 and SARS-CoV have an amino acid sequence similarity of up to 96%, and the structure of 3CLpro in SARS-CoV-2 has been solved [<xref ref-type="bibr" rid="CR82">82</xref>]. 3CLpro is a key protein of the virus, and the virus needs to use it to replicate RNA. Therefore, finding SARS-CoV-2 3CLpro inhibitors can provide a more effective way to fight COVID-19.</p></sec><sec id="Sec20"><title>RNA-dependent RNA polymerase (RdRp)</title><p id="Par35">As an RNA virus, SARS-CoV-2-encoded RdRp plays a key role in the virus&#x02019;s RNA replication. RdRp inhibitors can be used as broad-spectrum antiviral drugs against RNA viruses. The RdRp protein structure has a large and deep groove structural region as the active center of RNA synthesis. The sequence similarity of the RdRp proteins of SARS-CoV-2 and SARS-CoV is as high as 96%, and structural differences exist outside the active center [<xref ref-type="bibr" rid="CR82">82</xref>]. Therefore, high sequence conservation allows the development of RdRp inhibitors against SARS-CoV to be applied to the development of anti-SARS-CoV-2 drugs.</p></sec><sec id="Sec21"><title>TMPRSS2 (serine protease)</title><p id="Par36">A recent study showed that in addition to the use of the SARS-CoV receptor ACE2 to enter the cell, SARS-CoV-2 has two other proteins, cathepsin B and L(CatB/L) and TMPRSS2, that activate the S protein, help SARS-CoV enter the cell, and play a key role in the process of invasion of normal cells by SARS-CoV-2 [<xref ref-type="bibr" rid="CR84">84</xref>]. When a TMPRSS2 inhibitor is used in combination with a CatB/L inhibitor, they can completely inhibit the invasion of SARS-CoV-2. Therefore, TMPRSS2 may be a potential antiviral target.</p></sec></sec><sec id="Sec22"><title>Perspective</title><p id="Par37">This article provides an overview of published information on domestic research and the development of coronavirus-related therapeutic agents. The drug-repurposing effort summarized in this article focused primarily on agents currently known to be active against other RNA viruses, including SARS-CoV, MERS-CoV, influenza, HCV, and Ebola, as well as anti-inflammatory drugs. This information provides a strong intellectual groundwork for support of current and future research and development for the discovery and development of therapeutic agents for the treatment of COVID-19 and coronavirus-related diseases. However, there are still no officially approved specific antiviral drugs or vaccines for SARS-CoV-2, and supportive care remains a key to treatment. TCM has accumulated thousands of years of experience&#x000a0;in the treatment of pandemic and endemic diseases. Complementary and alternative treatments are still urgently needed for the management of patients with SARS-CoV-2 infection, and experiences in TCM are certainly worth examining. Many antiviral Chinese patent medicines, such as Shuanghuanglian oral solution and others, have been declared to have the effect of heat clearing and detoxifying, which could help clear viral respiratory pathogens and relieve symptoms according to TCM theory. Chinese patent medicine has been used in many historic epidemics, such as the previous two coronavirus outbreaks (SARS-CoV in 2013 and MERS-CoV in 2012) and seasonal epidemics caused by influenza viruses and dengue virus. Fighting against current epidemics also provides an opportunity to test the true value of TCM in treating emerging contagious diseases. It is encouraging that controlled clinical studies to evaluate the efficacy of TCM in the treatment of SARS-CoV were conducted and reported. We believe that specific and efficient antiviral drugs and therapy will arise from these ongoing and developing drugs, especially from the rich tradition of herbal medicines in China.</p></sec></body><back><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci China Life Sci</source><year>2020</year><volume>63</volume><fpage>457</fpage><lpage>60</lpage><?supplied-pmid 32009228?><pub-id pub-id-type="pmid">32009228</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>C</given-names></name><etal/></person-group><article-title>Recent advances in the detection of respiratory virus infection in humans</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>408</fpage><lpage>17</lpage><?supplied-pmid 31944312?><pub-id pub-id-type="pmid">31944312</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF-W</given-names></name><name><surname>Kok</surname><given-names>K-H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>To</surname><given-names>KK-W</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>221</fpage><lpage>36</lpage><?supplied-pmid 31987001?><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020: 2020.01.22.914952.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>SRLJ</given-names></name></person-group><article-title>Coronavirus pathogenesis</article-title><source>Adv Virus Res</source><year>2011</year><volume>81</volume><fpage>85</fpage><lpage>164</lpage><?supplied-pmid 7149603?><pub-id pub-id-type="pmid">22094080</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol Biol</source><year>2015</year><volume>1282</volume><fpage>1</fpage><lpage>23</lpage><?supplied-pmid 4369385?><pub-id pub-id-type="pmid">25720466</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name></person-group><article-title>MERS, SARS and other coronaviruses as causes of pneumonia</article-title><source>Respirology</source><year>2018</year><volume>23</volume><fpage>130</fpage><lpage>7</lpage><?supplied-pmid 29052924?><pub-id pub-id-type="pmid">29052924</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Netland</surname><given-names>J</given-names></name></person-group><article-title>Coronaviruses post-SARS: update on replication and pathogenesis</article-title><source>Nat Rev Microbiol</source><year>2009</year><volume>7</volume><fpage>439</fpage><lpage>50</lpage><?supplied-pmid 19430490?><pub-id pub-id-type="pmid">19430490</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name><name><surname>Kikkert</surname><given-names>M</given-names></name><name><surname>van Hemert</surname><given-names>MJ</given-names></name></person-group><article-title>Host factors in coronavirus replication</article-title><source>Curr Top Microbiol Immunol</source><year>2018</year><volume>419</volume><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">28643204</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><fpage>523</fpage><lpage>34</lpage><?supplied-pmid 27344959?><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/searchprojen.aspx">http://www.chictr.org.cn/searchprojen.aspx</ext-link>.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF-W</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>K-H</given-names></name><name><surname>To</surname><given-names>KK-W</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>514</fpage><lpage>23</lpage><?supplied-pmid 31986261?><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chunxia Zhou</surname><given-names>JS</given-names></name><name><surname>Xu</surname><given-names>Fengqin</given-names></name><name><surname>Jiang</surname><given-names>Shanping</given-names></name></person-group><article-title>Advance in research on treatment of influenza viral pneumonia [<italic>in Chinese</italic>].</article-title><source>Chin J Nosocomiol</source><year>2020</year><volume>30</volume><fpage>302</fpage><lpage>7</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BX</given-names></name><name><surname>Fish</surname><given-names>EN</given-names></name></person-group><article-title>The Yin and Yang of viruses and interferons</article-title><source>Trends Immunol</source><year>2012</year><volume>33</volume><fpage>190</fpage><lpage>7</lpage><?supplied-pmid 22321608?><pub-id pub-id-type="pmid">22321608</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>SD</given-names></name><name><surname>Majchrzak-Kita</surname><given-names>B</given-names></name><name><surname>Racine</surname><given-names>T</given-names></name><name><surname>Kozlowski</surname><given-names>HN</given-names></name><name><surname>Baker</surname><given-names>DP</given-names></name><name><surname>Hoenen</surname><given-names>T</given-names></name><etal/></person-group><article-title>A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><fpage>e0004364</fpage><?supplied-pmid 26752302?><pub-id pub-id-type="pmid">26752302</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriguchi</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>C</given-names></name></person-group><article-title>Treatment of SARS with human interferons</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1159</fpage><?supplied-pmid 14550718?><pub-id pub-id-type="pmid">14550718</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>YY</surname></name><name><surname>Yeung</surname><given-names>ML</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><etal/></person-group><article-title>Treatment with lopinavir/ritonavir or interferonbeta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><fpage>1904</fpage><lpage>13</lpage><?supplied-pmid 26198719?><pub-id pub-id-type="pmid">26198719</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvetkovic</surname><given-names>RS</given-names></name><name><surname>Goa</surname><given-names>KL</given-names></name></person-group><article-title>Lopinavir/ritonavir: a review of its use in the management of HIV infection</article-title><source>Drugs</source><year>2003</year><volume>63</volume><fpage>769</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">12662125</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>222</fpage><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VCC</given-names></name><name><surname>Hung</surname><given-names>IFN</given-names></name><name><surname>Wong</surname><given-names>MML</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>252</fpage><lpage>6</lpage><?supplied-pmid 1746980?><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>UJ</given-names></name><name><surname>Won</surname><given-names>E-J</given-names></name><name><surname>Kee</surname><given-names>S-J</given-names></name><name><surname>Jung</surname><given-names>S-I</given-names></name><name><surname>Jang</surname><given-names>H-C</given-names></name></person-group><article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-&#x003b1; for Middle East respiratory syndrome</article-title><source>Antivir Ther</source><year>2016</year><volume>21</volume><fpage>455</fpage><lpage>9</lpage><?supplied-pmid 26492219?><pub-id pub-id-type="pmid">26492219</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C-Y</given-names></name><name><surname>Jan</surname><given-names>J-T</given-names></name><name><surname>Ma</surname><given-names>S-H</given-names></name><name><surname>Kuo</surname><given-names>C-J</given-names></name><name><surname>Juan</surname><given-names>H-F</given-names></name><name><surname>Cheng</surname><given-names>Y-SE</given-names></name><etal/></person-group><article-title>Small molecules targeting severe acute respiratory syndrome human coronavirus</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>10012</fpage><lpage>7</lpage><?supplied-pmid 15226499?><pub-id pub-id-type="pmid">15226499</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title><source>Antimicrobial agents Chemother</source><year>2014</year><volume>58</volume><fpage>4875</fpage><lpage>84</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><etal/></person-group><article-title>A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1787</fpage><lpage>99</lpage><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv 2020: 2020.03.17.20037432.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaucourt</surname><given-names>S</given-names></name><name><surname>Vignuzzi</surname><given-names>M</given-names></name></person-group><article-title>Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance</article-title><source>Curr Opin Virol</source><year>2014</year><volume>8</volume><fpage>10</fpage><lpage>5</lpage><?supplied-pmid 24846716?><pub-id pub-id-type="pmid">24846716</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trang</surname><given-names>TP</given-names></name><name><surname>Whalen</surname><given-names>M</given-names></name><name><surname>Hilts-Horeczko</surname><given-names>A</given-names></name><name><surname>Doernberg</surname><given-names>SB</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature</article-title><source>Transpl Infect Dis</source><year>2018</year><volume>20</volume><fpage>e12844</fpage><?supplied-pmid 29360277?><pub-id pub-id-type="pmid">29360277</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e9;zode</surname><given-names>C</given-names></name><name><surname>Bronowicki</surname><given-names>J-P</given-names></name></person-group><article-title>Ideal oral combinations to eradicate HCV: the role of ribavirin</article-title><source>J Hepatol</source><year>2016</year><volume>64</volume><fpage>215</fpage><lpage>25</lpage><?supplied-pmid 26409316?><pub-id pub-id-type="pmid">26409316</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>P</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><etal/></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1986</fpage><lpage>94</lpage><?supplied-pmid 12682352?><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>CM</given-names></name><name><surname>Matukas</surname><given-names>LM</given-names></name><name><surname>Tomlinson</surname><given-names>GA</given-names></name><name><surname>Rachlis</surname><given-names>AR</given-names></name><name><surname>Rose</surname><given-names>DB</given-names></name><name><surname>Dwosh</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2801</fpage><lpage>9</lpage><?supplied-pmid 12734147?><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JWM</given-names></name><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Mok</surname><given-names>TYW</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>SYY</given-names></name><etal/></person-group><article-title>Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>686</fpage><lpage>9</lpage><?supplied-pmid 12885985?><pub-id pub-id-type="pmid">12885985</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>PKS</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>414</fpage><lpage>20</lpage><?supplied-pmid 15115870?><pub-id pub-id-type="pmid">15115870</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Michaelis</surname><given-names>M</given-names></name><name><surname>Baer</surname><given-names>PC</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name></person-group><article-title>Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>326</volume><fpage>905</fpage><lpage>8</lpage><?supplied-pmid 15607755?><pub-id pub-id-type="pmid">15607755</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omrani</surname><given-names>AS</given-names></name><name><surname>Saad</surname><given-names>MM</given-names></name><name><surname>Baig</surname><given-names>K</given-names></name><name><surname>Bahloul</surname><given-names>A</given-names></name><name><surname>Abdul-Matin</surname><given-names>M</given-names></name><name><surname>Alaidaroos</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>1090</fpage><lpage>5</lpage><?supplied-pmid 25278221?><pub-id pub-id-type="pmid">25278221</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A</given-names></name></person-group><article-title>Use of chloroquine in viral diseases</article-title><source>Lancet Infect Dis</source><year>2011</year><volume>11</volume><fpage>653</fpage><lpage>4</lpage><?supplied-pmid 21550312?><pub-id pub-id-type="pmid">21550312</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A</given-names></name><name><surname>Boelaert</surname><given-names>JR</given-names></name><name><surname>Cassone</surname><given-names>A</given-names></name><name><surname>Majori</surname><given-names>G</given-names></name><name><surname>Cauda</surname><given-names>R</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: an old drug against today&#x02019;s diseases?</article-title><source>Lancet Infect Dis</source><year>2003</year><volume>3</volume><fpage>722</fpage><lpage>7</lpage><?supplied-pmid 14592603?><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>71</lpage><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>2856</fpage><lpage>8</lpage><?supplied-pmid 22205743?><pub-id pub-id-type="pmid">22205743</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MJ</given-names></name><name><surname>Bergeron</surname><given-names>E</given-names></name><name><surname>Benjannet</surname><given-names>S</given-names></name><name><surname>Erickson</surname><given-names>BR</given-names></name><name><surname>Rollin</surname><given-names>PE</given-names></name><name><surname>Ksiazek</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source>Virol J</source><year>2005</year><volume>2</volume><fpage>69</fpage><?supplied-pmid 16115318?><pub-id pub-id-type="pmid">16115318</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Guangsheng Su XG. Progress in antiviral therapy of new coronavirus pneumonia [<italic>in Chinese</italic>]. Chinese Journal of Difficult and Complicated Cases 2020; <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/13.1316.R.20200226.0918.002.html">http://kns.cnki.net/kcms/detail/13.1316.R.20200226.0918.002.html</ext-link>.</mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaising</surname><given-names>J</given-names></name><name><surname>Polyak</surname><given-names>SJ</given-names></name><name><surname>P&#x000e9;cheur</surname><given-names>E-I</given-names></name></person-group><article-title>Arbidol as a broad-spectrum antiviral: an update</article-title><source>Antivir Res</source><year>2014</year><volume>107</volume><fpage>84</fpage><lpage>94</lpage><?supplied-pmid 24769245?><pub-id pub-id-type="pmid">24769245</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boriskin</surname><given-names>YS</given-names></name><name><surname>Leneva</surname><given-names>IA</given-names></name><name><surname>P&#x000e9;cheur</surname><given-names>EI</given-names></name><name><surname>Polyak</surname><given-names>SJ</given-names></name></person-group><article-title>Arbidol: a broad-spectrum antiviral compound that blocks viral fusion</article-title><source>Curr Med Chem.</source><year>2008</year><volume>15</volume><fpage>997</fpage><lpage>1005</lpage><?supplied-pmid 18393857?><pub-id pub-id-type="pmid">18393857</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;cheur</surname><given-names>E-I</given-names></name><name><surname>Borisevich</surname><given-names>V</given-names></name><name><surname>Halfmann</surname><given-names>P</given-names></name><name><surname>Morrey</surname><given-names>JD</given-names></name><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Prichard</surname><given-names>M</given-names></name><etal/></person-group><article-title>The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses</article-title><source>J Virol</source><year>2016</year><volume>90</volume><fpage>3086</fpage><lpage>92</lpage><?supplied-pmid 26739045?><pub-id pub-id-type="pmid">26739045</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawen Guan</surname><given-names>QD</given-names></name><name><surname>Jiang</surname><given-names>Haiming</given-names></name><name><surname>Zhao</surname><given-names>Jincun</given-names></name><name><surname>Yang</surname><given-names>Zifeng</given-names></name></person-group><article-title>Comparison of inhibitory effects of arbidol and Lianhuaqingwen Capsules on Middle East respiratory syndrome coronavirus in vitro and in vivo[<italic>in Chinese</italic>]</article-title><source>Guangdong Med J</source><year>2018</year><volume>39</volume><fpage>3454</fpage><lpage>8</lpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khamitov SIL</surname><given-names>RA</given-names></name><name><surname>Shchukina</surname><given-names>VN</given-names></name><name><surname>Borisevich</surname><given-names>SV</given-names></name><name><surname>Maksimov</surname><given-names>VA</given-names></name><name><surname>Shuster</surname><given-names>AM</given-names></name></person-group><article-title>[Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]</article-title><source>Vopr Virusol</source><year>2008</year><volume>53</volume><fpage>9</fpage><lpage>13</lpage></element-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.chinanews.com/gn/2020/02-04/9078596.shtml">https://www.chinanews.com/gn/2020/02-04/9078596.shtml</ext-link>.</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><fpage>64</fpage><lpage>8</lpage><?supplied-pmid 32037389?><pub-id pub-id-type="pmid">32037389</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Dancing with chemical formulae of antivirals: a personal account</article-title><source>Biochem Pharmacol.</source><year>2013</year><volume>86</volume><fpage>711</fpage><lpage>25</lpage><?supplied-pmid 23876344?><pub-id pub-id-type="pmid">23876344</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Dancing with chemical formulae of antivirals: A panoramic view (Part 2)</article-title><source>Biochem Pharmacol.</source><year>2013</year><volume>86</volume><fpage>1397</fpage><lpage>410</lpage><?supplied-pmid 24070654?><pub-id pub-id-type="pmid">24070654</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Kuno-Maekawa</surname><given-names>M</given-names></name><name><surname>Sangawa</surname><given-names>H</given-names></name><name><surname>Uehara</surname><given-names>S</given-names></name><name><surname>Kozaki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mechanism of action of T-705 against influenza virus</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>981</fpage><lpage>6</lpage><?supplied-pmid 15728892?><pub-id pub-id-type="pmid">15728892</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>New nucleoside analogues for the treatment of hemorrhagic fever virus infections</article-title><source>Chem-Asian J.</source><year>2019</year><volume>14</volume><fpage>3962</fpage><lpage>8</lpage><?supplied-pmid 31389664?><pub-id pub-id-type="pmid">31389664</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulangu</surname><given-names>S</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Davey</surname><given-names>RT</given-names></name><name><surname>Tshiani Mbaya</surname><given-names>O</given-names></name><name><surname>Proschan</surname><given-names>M</given-names></name><name><surname>Mukadi</surname><given-names>D</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of Ebola virus disease therapeutics</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><fpage>2293</fpage><lpage>303</lpage><?supplied-pmid 31774950?><pub-id pub-id-type="pmid">31774950</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cihlar</surname><given-names>T</given-names></name><name><surname>Ray</surname><given-names>AS</given-names></name></person-group><article-title>Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine</article-title><source>Antivir Res</source><year>2010</year><volume>85</volume><fpage>39</fpage><lpage>58</lpage><?supplied-pmid 19887088?><pub-id pub-id-type="pmid">19887088</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>PA</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name></person-group><article-title>Inhibitors of the hepatitis C virus polymerase; mode of action and resistance</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>5206</fpage><lpage>24</lpage><?supplied-pmid 26426038?><pub-id pub-id-type="pmid">26426038</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchesnokov</surname><given-names>EP</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Porter</surname><given-names>DP</given-names></name><name><surname>Gotte</surname><given-names>M</given-names></name></person-group><article-title>Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>326</fpage></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>ML</given-names></name><name><surname>Andres</surname><given-names>EL</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e00221</fpage><lpage>18</lpage><?supplied-pmid 29511076?><pub-id pub-id-type="pmid">29511076</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Won</surname><given-names>JJ</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase</article-title><source>Antivir Res</source><year>2019</year><volume>169</volume><fpage>104541</fpage><?supplied-pmid 31233808?><pub-id pub-id-type="pmid">31233808</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci Transl Med</source><year>2017</year><volume>9</volume><fpage>eaal3653</fpage><?supplied-pmid 28659436?><pub-id pub-id-type="pmid">28659436</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name><etal/></person-group><article-title>First case of 2019 novel Coronavirus in the United States</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>929</fpage><lpage>36</lpage><?supplied-pmid 7092802?><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schudt</surname><given-names>G</given-names></name><name><surname>Dolnik</surname><given-names>O</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Biedenkopf</surname><given-names>N</given-names></name><name><surname>Herwig</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name></person-group><article-title>Transport of Ebolavirus nucleocapsids is dependent on actin polymerization: live-cell imaging analysis of Ebolavirus-infected cells</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><issue> Suppl 2</issue><fpage>S160</fpage><lpage>6</lpage><?supplied-pmid 26038396?><pub-id pub-id-type="pmid">26038396</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainsford</surname><given-names>KD</given-names></name><name><surname>Parke</surname><given-names>AL</given-names></name><name><surname>Clifford-Rashotte</surname><given-names>M</given-names></name><name><surname>Kean</surname><given-names>WF</given-names></name></person-group><article-title>Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases</article-title><source>Inflammopharmacology</source><year>2015</year><volume>23</volume><fpage>231</fpage><lpage>69</lpage><?supplied-pmid 26246395?><pub-id pub-id-type="pmid">26246395</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C</given-names></name><name><surname>Daher</surname><given-names>W</given-names></name><name><surname>Chavain</surname><given-names>N</given-names></name><name><surname>Fandeur</surname><given-names>T</given-names></name><name><surname>Khalife</surname><given-names>J</given-names></name><name><surname>Dive</surname><given-names>D</given-names></name><etal/></person-group><article-title>Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities</article-title><source>J Med Chem</source><year>2006</year><volume>49</volume><fpage>2845</fpage><lpage>9</lpage><?supplied-pmid 16640347?><pub-id pub-id-type="pmid">16640347</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;&#x000a0;pii: ciaa237. 10.1093/cid/ciaa237.</mixed-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmor</surname><given-names>MF</given-names></name><name><surname>Kellner</surname><given-names>U</given-names></name><name><surname>Lai</surname><given-names>TYY</given-names></name><name><surname>Melles</surname><given-names>RB</given-names></name><name><surname>Mieler</surname><given-names>WF</given-names></name></person-group><article-title>Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)</article-title><source>Ophthalmology</source><year>2016</year><volume>123</volume><fpage>1386</fpage><lpage>94</lpage><?supplied-pmid 26992838?><pub-id pub-id-type="pmid">26992838</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.</mixed-citation></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="other">Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020: 2020.03.22.20040758.</mixed-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>D-W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>J-L</given-names></name><etal/></person-group><article-title>Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease</article-title><source>Biomed Pharmacother</source><year>2020</year><volume>121</volume><fpage>109652</fpage><?supplied-pmid 31734578?><pub-id pub-id-type="pmid">31734578</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function</article-title><source>BMC Complement Alternat Med.</source><year>2017</year><volume>17</volume><fpage>130</fpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Matsuura</surname><given-names>T</given-names></name><name><surname>Aoyagi</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Hmwe</surname><given-names>SS</given-names></name><name><surname>Date</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antiviral activity of glycyrrhizin against hepatitis C virus in vitro</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e68992</fpage><?supplied-pmid 23874843?><pub-id pub-id-type="pmid">23874843</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>2045</fpage><lpage>6</lpage><?supplied-pmid 12814717?><pub-id pub-id-type="pmid">12814717</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dezhong Cheng</surname><given-names>YL</given-names></name></person-group><article-title>Clinical effectiveness and case analysis in 54 NCP patients treated with Lianhuaqingwen Granules [<italic>in Chinese</italic>]</article-title><source>World Chin Med</source><year>2020</year><volume>15</volume><fpage>150</fpage><lpage>4</lpage></element-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional chinese medicine Lianhua Qingwen [<italic>in Chinese</italic>]. Chin J Exp Tradit Med Formul 2020; <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/11.3495.R.20200206.1500.004.html">http://kns.cnki.net/kcms/detail/11.3495.R.20200206.1500.004.html</ext-link>.</mixed-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Lv RB, Wang WJ, Li X. Clinical observation on 63 cases of suspected cases of new Coronavirus pneumonia treated by Chinese Medicine Lianhua Qingwen [<italic>in Chinese</italic>]. J Tradit Chin Med 2020; <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/11.2166.R.20200215.1633.004.html">http://kns.cnki.net/kcms/detail/11.2166.R.20200215.1633.004.html</ext-link>.</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Kao</surname><given-names>RYT</given-names></name><name><surname>Lu</surname><given-names>HT</given-names></name><name><surname>Fan</surname><given-names>KW</given-names></name><etal/></person-group><article-title>In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</article-title><source>J Clin Virol</source><year>2004</year><volume>31</volume><fpage>69</fpage><lpage>75</lpage><?supplied-pmid 15288617?><pub-id pub-id-type="pmid">15288617</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Bi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chi</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens</article-title><source>Poult Sci</source><year>2019</year><volume>98</volume><fpage>3548</fpage><lpage>56</lpage><?supplied-pmid 31220864?><pub-id pub-id-type="pmid">31220864</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>215</fpage><lpage>20</lpage><?supplied-pmid 32225176?><pub-id pub-id-type="pmid">32225176</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 10.1038/s41586-020-2179-y.&#x000a0;</mixed-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>C-L</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>3</lpage><?supplied-pmid 7164637?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>YM</given-names></name><name><surname>St John</surname><given-names>SE</given-names></name><name><surname>Mesecar</surname><given-names>AD</given-names></name></person-group><article-title>The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds</article-title><source>Antivir Res</source><year>2015</year><volume>115</volume><fpage>21</fpage><lpage>38</lpage><?supplied-pmid 25554382?><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>JS</given-names></name><name><surname>Lalonde</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>WR</given-names></name></person-group><article-title>Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV</article-title><source>Chembiochem</source><year>2020</year><volume>21</volume><fpage>730</fpage><lpage>8</lpage><?supplied-pmid 32022370?><pub-id pub-id-type="pmid">32022370</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Ju J, Kumar S, Li X, Jockusch S, Russo JJ. Nucleotide analogues as inhibitors of viral polymerases. bioRxiv 2020: 2020.01.30.927574.</mixed-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>.e8</lpage><?supplied-pmid 7102627?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref></ref-list></back></article>